Product/Composition:- | Fenofibrate Caplets and Capsules |
---|---|
Strength:- | 67 mg, 135 mg, 160 mg, and 145 mg |
Form:- | Caplets and Capsules |
Reference Brands:- | Tricor(US), Fenogal, Lipanor(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Fenofibrate caplets and capsules activate PPARα receptors, enhancing lipid metabolism. They reduce triglycerides, increase HDL cholesterol, and lower LDL cholesterol, supporting cardiovascular health. Benefits include improved lipid profiles, decreased risk of pancreatitis, and cardiovascular disease prevention, aiding long-term management of dyslipidemia and promoting overall heart health.
Fenofibrate caplets and capsules, marketed as Tricor in the US and as Fenogal or Lipanor in the EU, are approved for managing hypertriglyceridemia and hypercholesterolemia. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical trial and quality information, while the EU’s EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regional regulatory adherence supports timely approval, safe use, and worldwide availability of fenofibrate capsules, promoting cardiovascular health and lipid management globally.